AstraZeneca Invests US$50 Billion to Expand Drug Manufacturing and R&D in USA
Introduction:
AstraZeneca plans to invest US$50 billion to expand its drug manufacturing and research and development operations across the United States.
Features:
The new manufacturing facility in Virginia will produce drug substances for treatments targeting weight management and metabolic conditions, including oral GLP-1, baxdrostat, oral PCSK9, and combination small molecule products.
Manufacturing at the site will cover small molecules, peptides, and oligonucleotides.
The facility will utilise automation, artificial intelligence, and data analytics to support and optimise production processes.
Expansion includes R&D infrastructure in Gaithersburg (Maryland) and Kendall Square (Massachusetts), along with new sites in Rockville (Maryland), Tarzana (California), Mount Vernon (Indiana), and Coppell (Texas).
This includes continuous and specialty manufacturing, as well as facilities to support clinical trial supply.
The programme aligns with efforts to increase domestic pharmaceutical manufacturing and reduce reliance on international supply chains.
The combined projects are intended to support the company’s operational, research, and regulatory activities across the United States.
Specifications:
| Name | AstraZeneca |
| Type | New Construction |
| Budget | US$50 billion |
| Year | 2030 |
